CervoMed’s (CRVO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

A number of other research firms have also recently issued reports on CRVO. Roth Capital set a $9.00 target price on CervoMed in a research report on Monday, May 18th. Chardan Capital increased their target price on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research note on Monday, April 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price target on shares of CervoMed in a report on Wednesday, April 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.60.

CervoMed Stock Performance

Shares of CRVO stock opened at $3.08 on Wednesday. CervoMed has a fifty-two week low of $2.13 and a fifty-two week high of $13.13. The stock’s fifty day moving average price is $3.30 and its two-hundred day moving average price is $4.40. The company has a market cap of $41.67 million, a PE ratio of -0.94 and a beta of -0.68.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%. On average, equities analysts predict that CervoMed will post -2.84 EPS for the current fiscal year.

Insider Activity at CervoMed

In other news, Director Joshua S. Boger purchased 955,414 shares of CervoMed stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the completion of the acquisition, the director owned 1,795,865 shares in the company, valued at approximately $5,639,016.10. This trade represents a 113.68% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 35.80% of the company’s stock.

Institutional Investors Weigh In On CervoMed

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in CervoMed during the 1st quarter worth approximately $227,000. Rhumbline Advisers lifted its holdings in shares of CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the period. Marshall Wace LLP acquired a new position in shares of CervoMed during the second quarter worth $76,000. Jane Street Group LLC bought a new stake in shares of CervoMed in the second quarter worth $414,000. Finally, Vanguard Group Inc. grew its stake in shares of CervoMed by 1.0% in the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares during the last quarter. 25.15% of the stock is currently owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.